The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: A therapeutic perspective

Therapeutic Advances in Gastroenterology

Volumn 8, Issue 5, 2015, Pages 278-284

  Mosinska, Paula ^a   Storr, Martin ^a   Fichna, Jakub ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

AST 120; cardiovascular disease; chronic kidney disease; irritable bowel syndrome; kremezin

Indexed keywords

AST 120; AUTACOID; FARNESOID X RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 18; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UREMIC TOXIN;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADSORPTION; BLOATING; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL MOTILITY; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; INTESTINE TRANSIT TIME; IRRITABLE COLON; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; QUALITY OF LIFE; REVIEW;

EID: 84943255224     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X15587866     Document Type: Review

References (49)

1. Adijiang A. Goto S. Uramoto S. Nishijima F. Niwa T. (2008) Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant 23: 1892–1901.
2. Adijiang A. Niwa T. (2010) An oral sorbent, AST-120, increases Klotho expression and inhibits cell senescence in the kidney of uremic rats. Am J Nephrol 31: 160–164.
3. Akizawa T. Asano Y. Morita S. Wakita T. Onishi Y. Fukuhara S. et al. (2009) Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 54: 459–467.
4. Araki Y. Tsujikawa T. Andoh A. Sasaki M. Fujiyama Y. Bamba T., (2000) Therapeutic effects of an oral adsorbent on acute dextran sulphate sodium-induced colitis and its recovery phase in rats, especially effects of elimination of bile acids in gut lumen. Dig Liver Dis 32: 691–698.
5. Barbara G. Stanghellini V. de Giorgio R. Cremon C. Cottrell G. Santini D. et al. (2004) Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126: 693–702.
6. Bohlender J. Franke S. Stein G. Wolf G. (2005) Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 289: F645-F659.
7. Camilleri M. Di Lorenzo C. (2012) Brain–gut axis: from basic understanding to treatment of IBS and related disorders. J Pediatr Gastroenterol Nutr 54: 446–453.
8. Dou L. Bertrand E. Cerini C. Faure V. Sampol J. Vanholder R. et al. (2004) The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 65: 442–451.
9. El-Salhy M. Wendelbo I. Gundersen D. (2013) Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease. Mol Med Rep 8: 451–455.
10. Eutamene H. Theodorou V. Fioramonti J. Bueno L. (2003) Acute stress modulates the histamine content of mast cells in the gastrointestinal tract through interleukin-1 and corticotropin-releasing factor release in rats. J Physiol 553: 959–966.
11. Evenepoel P. Meijers B. Bammens B. Verbeke K. (2009) Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl (114): S12-S19.
12. Fujii H. Nishijima F. Goto S. Sugano M. Yamato H. Kitazawa R. et al. (2009) Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant 24: 2089–2095.
13. Furuhashi M. Hotamisligil G. (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7: 489–503.
14. Go A. Chertow G. Fan D. McCulloch C. Hsu C. (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305.
15. Inagaki T. Moschetta A. Lee Y. Peng L. Zhao G. Downes M. et al. (2006) Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 103: 3920–3925.
16. Inami Y. Hamada C. Seto T. Hotta Y. Aruga S. Inuma J. et al. (2014) Effect of AST-120 on endothelial dysfunction in adenine-induced uremic rats. Int J Nephrol 2014: 164125.
17. Ito S. Osaka M. Higuchi Y. Nishijima F. Ishii H. Yoshida M. (2010) Indoxyl sulfate induces leukocyte-endothelial interactions through up-regulation of E-selectin. J Biol Chem 285: 38869–38875.
18. Johnson D. Craven A. Isbel N. (2007) Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. Hemodial Int 11: 1–14.
19. Khan W. Ghia J. (2010) Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol 161: 19–27.
20. Konishi K. Nakano S. Tsuda S. Nakagawa A. Kigoshi T. Koya D. (2008) AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects. Diabetes Res Clin Pract 81: 310–315.
21. Lee S. Nam B. Kang E. Han S. Li J. Kim do H. et al. (2010) Effects of an oral adsorbent on oxidative stress and fibronectin expression in experimental diabetic nephropathy. Nephrol Dial Transplant 25: 2134–2141.
22. Maeda K. Hamada C. Hayashi T. Shou I. Wakabayashi M. Fukui M. et al. (2009) Long-term effects of the oral adsorbent, AST-120, in patients with chronic renal failure. J Int Med Res 37: 205–213.
23. Marier J. Lee J. Kambhampati S. Galitz L. Vargas R. Moberly J. et al. (2006) Effect of repeated oral administrations of the oral adsorbent AST-120 on serum creatinine and other markers of renal function. A randomized controlled study in patients with chronic kidney disease. Am J Nephrol 26: 136–141.
24. Martin-Garrido A. Brown D. Lyle A. Dikalova A. Seidel-Rogol B. Lassegue B. et al. (2011) NADPH oxidase 4 mediates TGF-beta-induced smooth muscle alpha-actin via p38MAPK and serum response factor. Free Radic Biol Med 50: 354–362.
25. Massy Z. Maziere C. Kamel S. Brazier M. Choukroun G. Tribouilloy C. et al. (2005) Impact of inflammation and oxidative stress on vascular calcifications in chronic kidney disease. Pediatr Nephrol 20: 380–382.
26. Matricon J. Meleine M. Gelot A. Piche T. Dapoigny M. Muller E. et al. (2012) Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 36: 1009–1031.
27. McGuckin M. Eri R. Simms L. Florin T. Radford-Smith G. (2009) Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 15: 100–113.
28. Meijers B. Van, Kerckhoven S. Verbeke K. Dehaen W. Vanrenterghem Y. Hoylaerts M. et al. (2009) The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 54: 891–901.
29. Miyamoto Y. Iwao Y. Tasaki Y. Sato K. Ishima Y. Watanabe H. et al. (2010) The uremic solute indoxyl sulfate acts as an antioxidant against superoxide anion radicals under normal-physiological conditions. FEBS Lett 584: 2816–2820.
30. Miyazaki T. Aoyama I. Ise M. Seo H. Niwa T. (2000) An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys. Nephrol Dial Transplant 15: 1773–1781.
31. Motojima M. Hosokawa A. Yamato H. Muraki T. Yoshioka T. (2003) Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 63: 1671–1680.
32. Muteliefu G. Shimizu H. Enomoto A. Nishijima F. Takahashi M. Niwa T. (2012) Indoxyl sulfate promotes vascular smooth muscle cell senescence with upregulation of p53, p21, and prelamin A through oxidative stress. Am J Physiol Cell Physiol 303: C126-C134.
33. Nakagawa N. Hasebe N. Sumitomo K. Fujino T. Fukuzawa J. Hirayama T. et al. (2006) An oral adsorbent, AST-120, suppresses oxidative stress in uremic rats. Am J Nephrol 26: 455–461.
34. Nakai K. Fujii H. Kono K. Goto S. Fukagawa M. Nishi S. (2011) Effects of AST-120 on left ventricular mass in predialysis patients. Am J Nephrol 33: 218–223.
35. Nakamura T. Sato E. Fujiwara N. Kawagoe Y. Suzuki T. Ueda Y. et al. (2011) Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation. Metabolism 60: 260–264.
36. O'Sullivan M. Clayton N. Breslin N. Harman I. Bountra C. McLaren A. et al. (2000) Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 12: 449–457.
37. Park J. Rhee P. Kim H. Lee J. Kim Y. Kim J. et al. (2006) Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 21: 71–78.
38. Schepers E. Meert N. Glorieux G. Goeman J. van der Eycken J. Vanholder R. (2007) P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 22: 592–596.
39. Schulman G. Vanholder R. Niwa T. (2014) AST-120 for the management of progression of chronic kidney disease. Int J Nephrol Renovasc Dis 7: 49–56.
40. Sinal C. Tohkin M. Miyata M. Ward J. Lambert G. Gonzalez F. (2000) Targeted disruption of the nuclear receptor FXR / BAR impairs bile acid and lipid homeostasis. Cell 102: 731–744.
41. Shibahara H. Shibahara N. (2010) Cardiorenal protective effect of the oral uremic toxin absorbent AST-120 in chronic heart disease patients with moderate CKD. J Nephrol 23: 535–540.
42. Shoji T. Wada A. Inoue K. Hayashi D. Tomida K. Furumatsu Y. et al. (2007) Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function. Nephron Clin Pract 105: c99–c107.
43. Soares R. (2014) Irritable bowel syndrome: a clinical review. World J Gastroenterol 20: 12144–12160.
44. Tack J. Miner P. Jr Fischer L. Harris M. (2011) Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome – a double-blind, placebo-controlled study. Aliment Pharmacol Ther 34: 868–877.
45. Ueda H. Shibahara N. Takagi S. Inoue T. Katsuoka Y. (2008) AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail 30: 856–860.
46. Vavassori P. Mencarelli A. Renga B. Distrutti E. Fiorucci S. (2009) The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 183: 6251–6261.
47. Vivinus-Nebot M. Dainese R. Anty R. Saint-Paul M. Nano J. Gonthier N. et al. (2012) Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol 107: 75–81.
48. Watanabe H. Miyamoto Y. Honda D. Tanaka H. Wu Q. Endo M. et al. (2013) p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int 83: 582–592.
49. Wu H. Sun H. Wang F. Yang M. Dong B. Liu G. (2014) Oral adsorbents for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev 10: CD007861.